Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
DBV Technologies (NASDAQ: DBVT) has released its half-year report regarding its liquidity contract with ODDO BHF. As of June 30, 2025, the liquidity account held 210,069 DBV Technologies shares and €171,301.08 in cash.
During H1 2025, the company executed 2,204 buy transactions and 2,398 sales transactions, with trading volumes of 1.16 million shares (€1.49M) purchased and 1.21 million shares (€1.56M) sold. This represents the activity since the contract's implementation on July 1, 2018, when the account started with 41,159 shares and €432,367.25.
DBV Technologies (NASDAQ: DBVT) ha pubblicato il suo rapporto semestrale riguardante il contratto di liquidità con ODDO BHF. Al 30 giugno 2025, il conto di liquidità deteneva 210.069 azioni di DBV Technologies e 171.301,08 € in contanti.
Nel primo semestre del 2025, la società ha effettuato 2.204 acquisti e 2.398 vendite, con volumi di scambio pari a 1,16 milioni di azioni (1,49 milioni di €) acquistate e 1,21 milioni di azioni (1,56 milioni di €) vendute. Questa attività si riferisce al periodo dalla stipula del contratto il 1° luglio 2018, quando il conto contava 41.159 azioni e 432.367,25 €.
DBV Technologies (NASDAQ: DBVT) ha publicado su informe semestral sobre el contrato de liquidez con ODDO BHF. Al 30 de junio de 2025, la cuenta de liquidez tenía 210.069 acciones de DBV Technologies y 171.301,08 € en efectivo.
Durante el primer semestre de 2025, la compañía realizó 2.204 compras y 2.398 ventas, con volúmenes de negociación de 1,16 millones de acciones (1,49 millones de €) compradas y 1,21 millones de acciones (1,56 millones de €) vendidas. Esta actividad abarca desde la implementación del contrato el 1 de julio de 2018, cuando la cuenta comenzó con 41.159 acciones y 432.367,25 €.
DBV Technologies (NASDAQ: DBVT)는 ODDO BHF와의 유동성 계약에 관한 반기 보고서를 발표했습니다. 2025년 6월 30일 기준으로 유동성 계좌에는 210,069주 DBV Technologies 주식과 171,301.08 유로의 현금이 보유되어 있습니다.
2025년 상반기 동안 회사는 2,204건의 매수 거래와 2,398건의 매도 거래를 실행했으며, 거래량은 116만 주(149만 유로) 매수와 121만 주(156만 유로) 매도로 집계되었습니다. 이는 2018년 7월 1일 계약이 시작되어 계좌에 41,159주와 432,367.25 유로가 있었던 시점부터의 활동입니다.
DBV Technologies (NASDAQ : DBVT) a publié son rapport semestriel concernant son contrat de liquidité avec ODDO BHF. Au 30 juin 2025, le compte de liquidité détenait 210 069 actions DBV Technologies et 171 301,08 € en liquidités.
Au cours du premier semestre 2025, la société a réalisé 2 204 achats et 2 398 ventes, avec des volumes de transactions de 1,16 million d’actions (1,49 M€) achetées et 1,21 million d’actions (1,56 M€) vendues. Cette activité couvre la période depuis la mise en place du contrat le 1er juillet 2018, date à laquelle le compte comptait 41 159 actions et 432 367,25 €.
DBV Technologies (NASDAQ: DBVT) hat seinen Halbjahresbericht zum Liquiditätsvertrag mit ODDO BHF veröffentlicht. Zum 30. Juni 2025 hielt das Liquiditätskonto 210.069 DBV Technologies Aktien und 171.301,08 € in bar.
Im ersten Halbjahr 2025 führte das Unternehmen 2.204 Kauftransaktionen und 2.398 Verkaufstransaktionen durch, mit Handelsvolumen von 1,16 Millionen Aktien (1,49 Mio. €) gekauft und 1,21 Millionen Aktien (1,56 Mio. €) verkauft. Diese Aktivität umfasst den Zeitraum seit Vertragsbeginn am 1. Juli 2018, als das Konto mit 41.159 Aktien und 432.367,25 € startete.
- None.
- None.
AMF Regulated Information
Châtillon, France, July 28, 2025
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF.
Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of June 30, 2025:
- 210,069 DBV Technologies shares,
€ 171,301.08 .
When the liquidity contract with ODDO BHF was implemented, as of July 1, 2018, the following assets were included in the liquidity account:
- 41,159 DBV Technologies shares,
€ 432,367.25 .
Over the period from January 1, 2025 to June 30, 2025, the following transactions were executed:
- 2204 buy transactions,
- 2398 sales transactions.
Over this same period, the volumes traded represented:
- 1,156,109 shares and
€ 1,492,280.33 on purchases, - 1,212,908 shares and
€ 1,556,651.52 on sales.
About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary VIASKIN® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (Ticker: DBVT; CUSIP: 23306J309).
For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com
Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com
Attachment
FAQ
What is the current balance of DBV Technologies' liquidity account with ODDO BHF as of June 30, 2025?
How many shares did DBVT trade under its liquidity contract in H1 2025?
What was the initial balance when DBV Technologies started its liquidity contract with ODDO BHF?
How many transactions did DBVT execute under the liquidity contract in H1 2025?
